Metformin can reduce lung inflammation, COVID-19 severity and mortality, as per the study done by the researchers on mice infected by the SARS-CoV-2 coronavirus.
Metformin can reduce lung inflammation, COVID-19 severity and mortality, as per the study done by the researchers on mice infected by the SARS-CoV-2 coronavirus. Metformin is a commonly used drug for Type-2 diabetes. It lowers glucose production in the liver, and improves the body’s response to insulin. Metformin may also possess anti-inflammatory properties, though the basis for this activity was not known.
‘Metformin may have therapeutic potential for treating various neurodegenerative and cardiovascular diseases in which there is more inflammation.’
Read More..
Researchers at University of California San Diego, assessed a mouse model with acute respiratory distress syndrome (ARDS), which is triggered by trauma and by bacterial or viral infections. It is a frequent cause of death in patients hospitalized with COVID-19.Read More..
Results in the Immunity showed that metformin administered to mice prior to or after exposure to bacterial endotoxin, a surrogate for bacterial pneumonia, resulted in the inhibition of ARDS onset and lessening of its symptoms.
Metformin reduced mortality in endotoxin-challenged mice and inhibited IL-1beta production and inflammasome in the lungs.
IL-1beta and IL-6, are cytokines that cause inflammation as an early immune response. Their amounts are increased in persons infected by SARS-CoV-2, creating "cytokine storms" in which the body starts attacking its own cells and tissues. They are signs of an acute immune response gone awry.
IL-1beta production depends on inflammasome, whose presence in lung tissue is found to be highly increased in deceased COVID-19 patients, researchers said.
Advertisement
Advertisement